Clover Raises $230 Million for Trimer-Tag Vaccines (including COVID-19) and Cancer Therapies

Clover Biopharma of Chengdu closed an oversubscribed $230 million Series C round for its protein-based vaccines and cancer therapies based on Trimer-Tag © technology. The company plans to start a global Phase II/III efficacy trial for its S-Trimer COVID-19 vaccine candidate in the first half of 2021. It has also begun making plans for producing hundreds of millions of vaccine doses by the end of the year. The Series C was co-led by GL Ventures, a Hillhouse venture fund, and Temasek. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.